Miltefosine effectively modulates the cytokine milieu in Indian post Kala-Azar dermal leishmaniasis

Journal of Infectious Diseases

Volumn 204, Issue 9, 2011, Pages 1427-1436

  Mukhopadhyay, Debanjan ^a   Das, Nilay Kanti ^b   Roy, Susmita ^a   Kundu, Sunanda ^a   Barbhuiya, J N ^b   Chatterjee, Mitali ^a  

^a Institute of Post Graduate Medical Education and Research   (India)

^b MEDICAL COLLEGE AND HOSPITAL   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMONY GLUCONATE; ARGINASE; B7 ANTIGEN; CD14 ANTIGEN; CD16 ANTIGEN; CD86 ANTIGEN; CYTOKINE; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; MILTEFOSINE; NITRITE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ADULT; ANTIGEN EXPRESSION; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; HUMAN; HUMAN CELL; IMMUNOMODULATION; INDIAN; MACROPHAGE ACTIVATION; MALE; MONOCYTE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SKIN LEISHMANIASIS; UPREGULATION;

ADOLESCENT; ADULT; AGED; ANTIGENS, CD14; ANTIGENS, CD80; ANTIGENS, CD86; ANTIPROTOZOAL AGENTS; CHILD; CYTOKINES; FEMALE; GPI-LINKED PROTEINS; HUMANS; IMMUNOLOGIC FACTORS; INDIA; LEISHMANIASIS, CUTANEOUS; LEISHMANIASIS, VISCERAL; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; PHOSPHORYLCHOLINE; RECEPTORS, IGG; SERUM; YOUNG ADULT;

EID: 80053418213     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jir551     Document Type: Article

References (40)

1. Ganguly S, Das NK, Barbhuiya JN, Chatterjee M. Post-kala-azar dermal leishmaniasisdan overview. Int J Dermatol 2010; 49:921-31.
2. Ismail A, El Hassan AM, Kemp K, et al. Immunopathology of post kalaazar dermal leishmaniasis (PKDL): T-cell phenotypes and cytokine profile. J Pathol 1999; 189:615-22.
3. Ganguly S, Das NK, Panja M, et al. Increased levels of interleukin-10 and IgG3 are hallmarks of Indian post-kala-azar dermal leishmaniasis. J Infect Dis 2008; 197:1762-71. (Pubitemid 351919642)
4. Reiner SL, Locksley RM. The regulation of immunity to Leishmania major. Annu Rev Immunol 1995; 13:151-77.
5. Tripathi P, Singh V, Naik S. Immune response to leishmania: paradox rather than paradigm. FEMS Immunol Med Microbiol 2007; 51:229-42. (Pubitemid 47547509)
6. Goto H, Prianti MG. Immunoactivation and immunopathogeny during active visceral leishmaniasis. Rev InstMed Trop Sao Paulo 2009; 51:241-6.
7. Kocyigit A, Gur S, Gurel MS, Bulut V, Ulukanligil M. Antimonial therapy induces circulating pro-inflammatory cytokines in patients with cutaneous leishmaniasis. Infect Immun 2002; 70:6589-91. (Pubitemid 35387885)
8. Soares G, Barral A, Costa JM, Barral-Netto M, Van Weyenbergh J. CD161 monocytes in human cutaneous leishmaniasis: increased ex vivo levels and correlation with clinical data. J Leukoc Biol 2006; 79:36-9. (Pubitemid 43054247)
9. Ansari NA, Sharma P, Salotra P. Circulating nitric oxide and C-reactive protein levels in Indian kala azar patients: correlation with clinical outcome. Clin Immunol 2007; 122:343-8. (Pubitemid 46216923)
10. Del Ara RM, Gonzalez-Polo RA, Caro A, et al. Diagnostic performance of arginase activity in colorectal cancer. Clin Exp Med 2002; 2:53-7. (Pubitemid 34743948)
11. Grage-Griebenow E, Flad HD, Ernst M. Heterogeneity of human peripheral blood monocyte subsets. J Leukoc Biol 2001; 69:11-20. (Pubitemid 32095112)
12. Rudd CE, Taylor A, Schneider H. CD28 and CTLA-4 coreceptor expression and signal transduction. Immunol Rev 2009; 229:12-26.
13. Ganguly S, Mukhopadhyay D, Das NK, et al. Enhanced lesional Foxp3 expression and peripheral anergic lymphocytes indicate a role for regulatory T cells in Indian PKDL. J Invest Dermatol 2010; 130:1013-22.
14. Nylen S, Gautam S. Immunological perspectives of leishmaniasis. J Glob Infect Dis 2010; 2:135-46.
15. Das P, Lahiri A, Lahiri A, Chakravortty D. Modulation of the arginase pathway in the context of microbial pathogenesis: a metabolic enzyme moonlighting as an immune modulator. PLoS Pathog 2010; 6:e1000899.
16. Van Assche T, Deschacht M, da Luz IAR, Maes L, Cos P. Leishmaniamacrophage interactions: insights into the redox biology. Free Radic Biol Med 2011; doi:10.1016/j.freeradbiomed.2011.05.011.
17. Wadhone P, Maiti M, Agarwal R, Kamat V, Martin S, Saha B. Miltefosine promotes IFN-gamma-dominated anti-leishmanial immune response. J Immunol 2009; 182:7146-54.
18. Paris C, Loiseau PM, Bories C, Bréard J. Miltefosine induces apoptosislike death in Leishmania donovani promastigotes. Antimicrob Agents Chemother 2004; 48:852-9. (Pubitemid 38280335)
19. Saraiva VB, Gibaldi D, Previato JO, et al. Proinflammatory and cytotoxic effects of hexadecylphosphocholine (miltefosine) against drug resistant strains of Trypanosoma cruzi. Antimicrob Agents Chemother 2002; 46:3472-7. (Pubitemid 35192913)
20. Escobar P, Yardley V, Croft SL. Activities of hexadecylphosphocholine (miltefosine), amBisome, and sodium stibogluconate (pentostam) against Leishmania donovani in immunodeficient SCID mice. Antimicrob Agents Chemother 2001; 45:1872-5. (Pubitemid 32466363)
21. Vehmeyer K, Scheurich P, Eibl H, Unger C. Hexadecylphosphocholine mediated enhancement of T cell responses to interleukin-2. Cell Immunol 1991; 137:232-8.
22. Ziegler-Heitbrock L. The CD141 CD161 blood monocytes: their role in infection and inflammation. J Leukoc Biol 2007; 81:584-92. (Pubitemid 46393535)
23. Pereira LL, Dorta ML, Pereira AJ, et al. Increase of NK cells and proinflammatory monocytes are associated with the clinical improvement of diffuse cutaneous leishmaniasis after immunochemotherapy with BCG/Leishmania antigens. Am J Trop Med Hyg 2009; 81: 378-83.
24. Somoza C, Lanier LL. T-cell costimulation via CD28-CD80/CD86 and CD40-CD40 ligand interactions. Res Immunol 1995; 146:171-6.
25. Ansari NA, Saluja S, Salotra P. Elevated levels of interferon-gamma, interleukin-10, and interleukin-6 during active disease in Indian kala azar. Clin Immunol 2006; 119:339-45.
26. Cenini P, Berhe N, Hailu A, McGinnes K, Frommel D. Mononuclear cell subpopulations and cytokine levels in human visceral leishmaniasis before and after chemotherapy. J Infect Dis 1993; 168:986-93. (Pubitemid 23282575)
27. Hirota K, Akahoshi T, Endo H, Kondo H, Kashiwazaki S. Production of interleukin-8 by cultured synovial cells in response to interleukin-1 and tumor necrosis factor. Rheumatol Int 1992; 12:13-6.
28. Teixeira MJ, Teixeira CR, Andrade BB, Barral-Netto M, Barral A. Chemokines in host-parasite interactions in leishmaniasis. Trends Parasitol 2006; 22:32-40. (Pubitemid 43017202)
29. Laufs H, Müller K, Fleischer J, et al. Intracellular survival of Leishmania major in neutrophil granulocytes after uptake in the absence of heatlabile serum factors. Infect Immun 2002; 70:826-35. (Pubitemid 34083846)
30. Sen R. Chatterjee M. Plant derived therapeutics for the treatment of leishmaniasis. Phytomedicine 2011; doi:10.1016/j.phymed.2011.03. 004.
31. Nylen S, Akuffo H. Tracing immunity to human leishmaniasis. Future Microbiol 2009; 4:241-54.
32. Babaloo Z, Kaye PM, Eslami MB. Interleukin-13 in Iranian patients with visceral leishmaniasis: relationship to other Th2 and Th1 cytokines. Trans R Soc Trop Med Hyg 2001; 95:85-8. (Pubitemid 34202236)
33. Raziuddin S, Abdalla RE, el-Awad EH, al-Janadi M. Immunoregulatory and proinflammatory cytokine production in visceral and cutaneous leishmaniasis. J Infect Dis 1994; 170:1037-40. (Pubitemid 24296594)
34. Cunningham AC. Parasitic adaptive mechanisms in infection by Leishmania. Exp Mol Pathol 2002; 72:132-41.
35. Sarkar A, Saha P, Mandal G, et al. Monitoring of intracellular nitric oxide in leishmaniasis: its applicability in patients with visceral leishmaniasis. Cytometry A 2011; 79:35-45.
36. Brunet LR. Nitric oxide in parasitic infections. Int Immunopharmacol 2001; 1:1457-67. (Pubitemid 32622790)
37. Bogdan C. Nitric oxide and the immune response. Nat Immunol 2001; 2:907-16. (Pubitemid 32976162)
38. Osorio YE, Zhao W, Espitia C, et al. Dominant arginase expression in a model of progressive visceral leishmaniasis. FASEB J 2008; 22:860.20.
39. Ansari NA, Ramesh V, Salotra P. Immune response following miltefosine therapy in a patient with post-kala-azar dermal leishmaniasis. Trans R Soc Trop Med Hyg 2008; 102:1160-2.
40. Ansari NA, Ramesh V, Salotra P. Interferon (IFN)-gamma, tumor necrosis factor-alpha, interleukin-6, and IFN-gamma receptor 1 are the major immunological determinants associated with post-kala azar dermal leishmaniasis. J Infect Dis 2006; 194:958-65. (Pubitemid 44454081)